Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,288,596,915.49, a decrease of 7.06% compared to CNY 1,386,540,192.69 in the same period last year[10]. - The net profit attributable to shareholders for the first half of 2021 was CNY 457,282,913.56, down 10.64% from CNY 511,739,953.40 in the previous year[10]. - The net profit after deducting non-recurring gains and losses was CNY 395,891,509.69, a decrease of 14.92% compared to CNY 465,318,823.58 in the same period last year[10]. - The total revenue for the first half of 2021 reached CNY 2,273,695,533.30, an increase from CNY 1,548,264,921.35 in the same period of 2020[80]. - The net profit for the first half of 2021 was CNY 836,403,603.30, compared to CNY 291,088,036.75 in the first half of 2020, representing a growth of approximately 187%[79]. - The total comprehensive income for the first half of 2021 was CNY 449,873,838.47, down from CNY 505,314,841.02 in the same period of 2020[76]. - The total comprehensive income for the period was CNY 457.28 million, reflecting a strong performance despite the challenges faced[88]. Revenue Breakdown - Revenue from blood products accounted for 98.72% of total revenue, with a total of ¥1,272,136,518.25, down 8.28% year-on-year[23]. - Vaccine products saw a significant increase in revenue, reaching ¥9,303,720.74, up 260.67% compared to the previous year[23]. - The company's revenue primarily comes from the production and sale of blood products and vaccines[194]. Cash Flow and Assets - The net cash flow from operating activities increased by 57.05% to CNY 740,915,819.61, compared to CNY 471,757,731.71 in the previous year[10]. - The company's cash and cash equivalents at the end of the reporting period were CNY 1,251,187,912.07, an increase in proportion to total assets from 10.34% to 13.12%[26]. - Cash and cash equivalents as of June 30, 2021, amounted to ¥1,251,187,912.07, an increase from ¥1,038,328,045.65 at the end of 2020[66]. - The cash flow from operating activities for the first half of 2021 was CNY 740,915,819.61, up from CNY 471,757,731.71 in the first half of 2020[81]. Research and Development - Research and development expenses increased by 54.87% to ¥123,222,887.69, indicating a strong focus on innovation[21]. - The company has a strong commitment to R&D in innovative drugs, with ongoing clinical trials for multiple monoclonal antibodies[14]. - The company is focused on developing innovative drugs and biosimilars to address major diseases, enhancing its core competitiveness through strategic partnerships[17]. Market Position and Strategy - The company operates in the blood products, vaccines, and gene engineering sectors, with a diverse range of 34 specifications across 11 blood product varieties[14]. - The company aims to enhance market supply of influenza vaccines and strengthen market expansion efforts in the second half of the year[18]. - The company is the largest influenza vaccine production base in China, with multiple vaccines including quadrivalent influenza virus split vaccine and recombinant hepatitis B vaccine in the market[16]. - The blood products market is expected to grow due to increasing health awareness and aging population, with a shift in demand from human albumin to immunoglobulin and coagulation factor products[16]. Shareholder Information - The total number of shares increased to 1,824,366,726, with 86.09% being unrestricted shares[52]. - The largest shareholder, Chongqing Shengkang Biotechnology Development Co., Ltd., held 15.04% of shares, totaling 274,438,679 shares[59]. - The second largest shareholder, Hong Kong Kekang Co., Ltd., held 13.15% of shares, totaling 239,893,954 shares[59]. Quality and Compliance - The company emphasizes quality management in vaccine production, adhering to the principle of "biological product safety without limits"[17]. - The company emphasizes quality control as a critical measure to mitigate potential risks related to product safety[36]. - The company has not faced any environmental penalties during the reporting period and adheres to relevant environmental protection laws[42]. Financial Position - The total assets at the end of the reporting period were CNY 9,533,510,216.46, a decrease of 5.03% from CNY 10,038,637,131.75 at the end of the previous year[10]. - The net assets attributable to shareholders at the end of the reporting period were CNY 7,493,509,387.83, down 0.47% from CNY 7,528,539,476.95 at the end of the previous year[10]. - The company's total equity at the end of the period was CNY 8.10 billion, showing a stable financial position[87]. Dividends and Shareholder Returns - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[2]. - The company has implemented an employee stock incentive plan, unlocking 5,152,875 restricted shares for 111 individuals as part of its 2018 plan[40]. Legal and Regulatory Matters - The company did not experience any overdue receivables or impairment losses from entrusted financial management[48]. - There were no major litigation or arbitration matters during the reporting period[45]. - The company's semi-annual financial report has not been audited[44].

Financial Performance - The company's operating revenue for 2020 was CNY 5,023,206,263.40, representing a 35.76% increase compared to CNY 3,699,941,990.20 in 2019[17] - The net profit attributable to shareholders for 2020 was CNY 1,613,105,262.32, a 25.69% increase from CNY 1,283,449,049.98 in the previous year[17] - The net profit after deducting non-recurring gains and losses was CNY 1,477,519,424.79, up 28.83% from CNY 1,146,854,058.97 in 2019[17] - The basic earnings per share for 2020 was CNY 0.8873, reflecting a 25.59% increase from CNY 0.7065 in 2019[17] - The total assets at the end of 2020 were CNY 10,038,637,131.75, a 32.38% increase from CNY 7,583,197,994.71 at the end of 2019[17] - The net assets attributable to shareholders at the end of 2020 were CNY 7,528,539,476.95, which is a 15.06% increase from CNY 6,543,127,592.63 in 2019[17] - The net cash flow from operating activities for 2020 was CNY 1,325,292,979.33, a decrease of 2.75% compared to CNY 1,362,760,281.36 in 2019[17] - The weighted average return on equity for 2020 was 23.39%, an increase of 3.50% from 19.89% in 2019[17] Revenue and Profit Distribution - The company plans to distribute a cash dividend of CNY 3 per 10 shares, based on a total of 1,824,366,726 shares[5] - The company reported a net profit of CNY 490,021,387.70 for 2020, with a distributable profit of CNY 441,019,248.93 after statutory surplus reserve allocation[90] - The cash dividend for 2020 represents 33.93% of the net profit attributable to ordinary shareholders[94] - The company has committed to a minimum cash dividend ratio of 80% during profit distributions, given its mature development stage and absence of major capital expenditure plans[96] - The remaining undistributed profits after the 2020 dividend distribution will amount to 969,840,511.86 yuan[97] Business Segments and Products - The main business includes blood products, vaccines, and innovative drug development, with a focus on high plasma utilization rates and a wide range of products[27] - The company has developed multiple blood products, including human albumin and immunoglobulins, which are critical for various medical treatments[28] - The vaccine segment includes products like the influenza vaccine and recombinant hepatitis B vaccine, aimed at preventing infectious diseases[27] - The company is actively engaged in clinical trials for innovative drugs, having obtained clinical trial approvals for several monoclonal antibodies[27] - The company achieved a total of 23.15 million doses of flu vaccine batch approvals, accounting for 40.16% of the national total, with the quadrivalent flu vaccine representing 61.41% of its category[32] Market Position and Industry Trends - The company maintains a strong market position in the blood products industry, with a comprehensive product range and high utilization efficiency[27] - The blood products market is experiencing growth, with the combined plasma collection of four major companies accounting for over 50% of the national total in 2020, reflecting increasing industry concentration[35] - The actual demand for plasma in China exceeds 14,000 tons, while the total plasma collection in 2020 was only around 8,300 tons, reflecting a significant supply-demand gap[77] - The vaccine market in China is expected to grow significantly due to rising public awareness and government support for vaccination programs[79] Research and Development - The company is committed to innovation in drug development, particularly in monoclonal antibodies and biosimilars, to create new profit growth points[33] - The company has established a strong research and development platform, focusing on innovative biopharmaceuticals and gene-engineered drugs[40] - The company is focusing on the development of new vaccine products, including the completion of clinical trials for the quadrivalent flu vaccine for children[32] - The company aims to enhance its R&D efforts in vaccines, innovative drugs, and biosimilars, with a focus on improving production processes and product structure to increase plasma utilization[80] Strategic Partnerships and Collaborations - The company is expanding its strategic partnerships with domestic and international firms to enhance its core competitiveness in the biopharmaceutical industry[32] - The company is actively pursuing strategic collaborations with domestic and international enterprises to enhance its core competitiveness[41] Corporate Governance and Compliance - The company has established a complete and independent governance structure, complying with relevant laws and regulations, ensuring strong independence and standardized information disclosure[176] - The company has maintained a clear separation from its controlling shareholder in terms of business, personnel, assets, institutions, and finance, demonstrating complete independence[181] - The company has implemented a transparent and effective performance evaluation and incentive mechanism for its directors, supervisors, and senior management[179] - The company has established effective communication channels with shareholders to ensure equal treatment and rights for all shareholders, especially minority shareholders[177] Employee Management and Development - The company has a total of 2,887 employees, with 1,239 in production, 211 in sales, 1,142 in technical roles, 57 in finance, and 238 in administration[171] - The company emphasizes employee training in areas such as microbiology, safety, and professional knowledge to enhance overall employee capabilities[173] - The company has a structured salary management system that adjusts employee compensation based on operational performance and regional living costs[172] Risk Management - The company has established a comprehensive quality assurance system to mitigate risks related to product safety and ensure the reliability of its pharmaceutical products[82] - The company faces potential risks from rising raw plasma costs, which could impact the overall gross profit margin of blood products[83] - The company emphasizes the importance of regulatory compliance for its plasma collection stations to avoid operational risks[83] Shareholder Information - The company’s total share capital after the capital increase is 1,824,366,726 shares[143] - The largest shareholder, Ankang, holds 325,683,401 shares, representing 17.85% of the total shares[146] - The company’s controlling shareholder is Ankang, a natural person, who has no foreign residency rights[148] - The total number of common shareholders increased from 185,885 to 217,008 during the reporting period[145]

Financial Performance - Operating revenue for the reporting period was ¥1,686,255,411.15, representing a year-on-year increase of 16.46%[3] - Net profit attributable to shareholders was ¥452,450,340.61, showing a slight decrease of 0.96% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥409,349,482.90, down 4.70% year-on-year[3] - Basic earnings per share for the reporting period were ¥0.2481, a decrease of 0.96% compared to the same period last year[3] - The weighted average return on net assets was 5.81%, down 1.46% from the previous year[3] - Total operating revenue for the third quarter was CNY 1,041,593,101.87, an increase from CNY 689,522,474.60 in the same period last year, representing a growth of approximately 51%[27] - Net profit for the third quarter reached CNY 562,709,875.25, compared to CNY 517,758,151.21 in the previous year, reflecting an increase of about 8.7%[28] - The company reported a total profit of CNY 698,535,244.69 for the quarter, compared to CNY 600,328,027.55 in the same quarter last year, marking a growth of around 16.4%[28] - Net profit for the period was CNY 1,068,024,716.27, compared to CNY 1,015,886,901.14 in the previous period, indicating a growth of 5.1%[36] - The company reported a total comprehensive income of CNY 1,068,024,716.27, up from CNY 1,015,886,901.14, reflecting a growth of 5.1%[38] Assets and Liabilities - Total assets at the end of the reporting period reached ¥8,833,234,348.75, an increase of 16.48% compared to the end of the previous year[3] - The total liabilities increased to ¥304,878,599.52 from ¥138,980,247.20 year-over-year, indicating a significant rise in financial obligations[26] - The equity attributable to shareholders of the parent company rose to ¥6,960,824,728.64, compared to ¥6,543,127,592.63 in the previous year, marking an increase of approximately 6.4%[23] - The total assets as of September 30, 2020, amounted to ¥4,165,374,660.16, slightly down from ¥4,203,418,446.89 at the end of 2019[25] Cash Flow - The net cash flow from operating activities was ¥93,506,692.63, a decrease of 57.87% compared to the previous year[3] - Cash and cash equivalents decreased by 60.74% compared to the beginning of the period, primarily due to the investment of idle funds in financial products[10] - The net cash flow from financing activities increased by 54.23% compared to the same period last year, mainly due to increased cash from borrowings[10] - The cash flow from operating activities generated a net amount of CNY 565.26 million, compared to CNY 761.88 million in the previous year, reflecting a decline of about 25.8%[43] - The net cash flow from financing activities was negative at CNY -144.22 million, an improvement from CNY -315.09 million in the previous year[44] Investments and Expenses - Research and development expenses increased by 38.72% compared to the same period last year, reflecting higher R&D investment[10] - Sales expenses surged to CNY 567,250,555.86, compared to CNY 293,494,455.22, marking an increase of 93.4%[35] - The investment income from associates and joint ventures showed a loss of CNY 8,437,474.19, compared to a gain of CNY 18,799,920.44 in the previous period[35] - The company reported investment income of CNY 29,637,829.12, significantly higher than CNY 2,630,173.82 from the previous year[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 163,657[6] - The largest shareholder, An Kang, held 17.85% of the shares, totaling 325,683,401 shares[6] Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies, although specific figures were not disclosed in the reports[36] Other Information - The company initiated the spin-off of its vaccine subsidiary for listing on the Shenzhen Stock Exchange's Growth Enterprise Market, introducing strategic investors[11] - The company did not undergo an audit for the third quarter report[48] - The report indicates that the new revenue and leasing standards were not applicable for the current year[48]

Financial Performance - The company's operating revenue for the first half of 2020 was RMB 1,386,540,192.69, a decrease of 1.15% compared to RMB 1,402,608,966.25 in the same period last year[11]. - The net profit attributable to shareholders of the listed company was RMB 511,739,953.40, an increase of 0.94% from RMB 506,977,015.08 in the previous year[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 465,318,823.58, up by 0.72% compared to RMB 461,978,237.61 last year[11]. - The net cash flow from operating activities was RMB 471,757,731.71, down by 12.63% from RMB 539,952,706.48 in the same period last year[11]. - The basic earnings per share were RMB 0.2805, reflecting a 0.90% increase from RMB 0.2780 in the previous year[11]. - The total assets at the end of the reporting period were RMB 7,809,145,343.79, an increase of 2.98% from RMB 7,583,197,994.71 at the end of the previous year[11]. - The net assets attributable to shareholders of the listed company were RMB 6,505,098,238.03, a decrease of 0.58% from RMB 6,543,127,592.63 at the end of the previous year[11]. - The weighted average return on net assets was 7.32%, down by 1.44% from 8.76% in the previous year[11]. Dividends and Profit Distribution - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[2]. - The company has committed to distributing at least 10% of the annual distributable profits as cash dividends from 2018 to 2020, with a cumulative distribution of no less than 30% of the average annual distributable profits over the three years[45]. Business Operations and Market Presence - The main business includes blood products, vaccines, and the development of innovative drugs and biosimilars, with a focus on high plasma utilization and a wide range of products[16]. - The company has developed 11 types of blood products, including human albumin and immunoglobulins, which are critical for medical emergencies and specific diseases[16]. - The vaccine segment includes several products such as influenza vaccines and recombinant hepatitis B vaccines, aimed at preventing infectious diseases[16]. - The company is actively conducting clinical trials for innovative drugs, having obtained clinical trial approvals for multiple monoclonal antibodies[16]. - The company emphasizes the importance of blood products in medical treatments, highlighting their irreplaceable role in certain therapies[17]. - The company is expanding its market presence through the development of new products and technologies in the biopharmaceutical sector[16]. - The company aims to expand its vaccine business and enhance market penetration for flu vaccines and quadrivalent flu vaccines in the second half of the year[19]. Research and Development - Research and development expenses increased by 16.67% to CNY 79,566,049.22, reflecting the company's focus on new product development and process optimization[25]. - The company has established a robust research and development platform, focusing on key technologies and product innovation in blood products, vaccines, and gene-engineered drugs[21]. - The company is committed to innovation-driven development, focusing on the research and production of recombinant proteins and biosimilars to create new profit growth points[19]. - The company has developed a new generation of intravenous immunoglobulin with a dual virus removal technology, which has received a clinical trial notification[24]. Financial Management and Risks - There are no significant adverse risk factors affecting the company's production, operation, financial status, or ongoing profitability[2]. - The company faces potential risks related to the rising costs of raw plasma, which could impact profit margins due to increased competition and price volatility in the blood products market[41]. - The company is committed to strengthening its research and development capabilities to address potential risks associated with new product development and to enhance the conversion of R&D results into marketable products[41]. - The company has implemented measures to ensure compliance and effective management of its plasma collection stations to mitigate regulatory risks[40]. Shareholder Information - The total number of shareholders at the end of the reporting period was 90,000, with the top five shareholders holding a combined 54.63% of the shares[66]. - The largest shareholder, Ankang, holds 17.85% of the shares, amounting to 325,683,401 shares[66]. - The company’s shareholding structure shows a reduction in the proportion of limited shares from 14.22% to 14.11% after the recent changes[60]. Compliance and Governance - The company has not experienced any major litigation or arbitration matters during the reporting period[46]. - The company has not conducted any significant related party transactions during the reporting period[48]. - The company has not made any non-operating fund occupation by controlling shareholders or their related parties during the reporting period[50]. - The company operates under the assumption of going concern, with no significant doubts about its ability to continue operations for the next 12 months[119]. Environmental and Social Responsibility - The company reported no significant environmental pollution incidents or legal penalties during the reporting period, adhering to various environmental protection laws[56]. - The company has engaged in various poverty alleviation initiatives, although specific metrics and outcomes were not detailed in the report[56]. Accounting and Financial Reporting - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring a true and complete reflection of the company's financial status[121]. - The company uses Renminbi as its functional currency for accounting purposes[122]. - The company recognizes revenue when control of goods or services is transferred to the customer, following specific performance obligations outlined in contracts[199].

Financial Performance - The company's operating revenue for Q1 2020 was ¥677,541,355.35, a decrease of 2.62% compared to ¥695,786,897.01 in the same period last year[3]. - The net profit attributable to shareholders was ¥247,286,426.50, down 4.71% from ¥259,506,104.27 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥243,809,415.41, an increase of 1.49% compared to ¥240,220,781.73 in the previous year[3]. - The basic earnings per share were ¥0.1762, down 4.76% from ¥0.1850 year-on-year[3]. - The total comprehensive income for the period was CNY 237.43 million, compared to CNY 254.61 million in the previous year, reflecting a decline of 6.7%[28]. - The total profit for the period was CNY 152.80 million, an increase of 30.5% compared to CNY 117.00 million in the previous year[30]. Cash Flow - The net cash flow from operating activities was ¥95,887,096.67, a significant decrease of 49.03% from ¥188,118,276.43 in the same period last year[3]. - The company's cash flow from operating activities was CNY 568.10 million, a decrease of 29.0% from CNY 798.90 million in the same period last year[32]. - Cash received from sales of goods and services was ¥225,055,585.85, down 31.3% from ¥327,368,860.01 in the previous year[35]. - The net cash flow from financing activities was ¥53,695,247.10, an increase from ¥47,900,076.49 in the same period last year[34]. - The ending balance of cash and cash equivalents was ¥359,519,051.88, compared to ¥308,483,918.02 at the end of Q1 2019[34]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,791,312,700.57, an increase of 2.74% from ¥7,583,197,994.71 at the end of the previous year[3]. - The total liabilities were CNY 666,104,639.73 as of March 31, 2020, down from CNY 699,256,000.55 at the end of December 2019[19]. - The total equity attributable to the parent company reached CNY 6,794,251,046.01 as of March 31, 2020, compared to CNY 6,543,127,592.63 at the end of December 2019[20]. - Cash and cash equivalents increased to CNY 537,295,290.32 from CNY 417,421,654.58, indicating improved liquidity[21]. - Accounts receivable rose significantly to CNY 354,642,144.54 from CNY 183,520,874.00, suggesting increased sales or credit terms[21]. - Inventory decreased to CNY 460,551,504.40 from CNY 574,243,029.78, which may indicate better inventory management[21]. Shareholder Information - The company reported a total of 59,443 common shareholders at the end of the reporting period[6]. - The top shareholder, Chongqing Shengkang Biotechnology Development Co., Ltd., held 15.05% of the shares, totaling 211,106,676 shares[6]. Expenses - Sales expenses decreased by 55.20% compared to the same period last year, mainly due to a reduction in promotional consulting fees[11]. - Financial expenses decreased by 165.20% compared to the same period last year, primarily due to an increase in interest income during the period[11]. - The company experienced a significant reduction in sales expenses, which dropped to CNY 15.55 million from CNY 58.73 million year-over-year, a decrease of 73.5%[29]. - Research and development expenses increased significantly to CNY 20.21 million, up 155.5% from CNY 7.92 million in the same period last year[29]. Other Financial Metrics - The weighted average return on net assets was 3.71%, down 0.87% from 4.58% in the same period last year[3]. - The company reported a net investment income of CNY 14,633,617.69, slightly down from CNY 15,822,928.62 in the previous period[25]. - The company reported a decrease in financial asset impairment losses, with a loss of CNY 5.43 million compared to no losses reported in the previous year[30]. Additional Information - The first quarter report was not audited[38]. - The company is focusing on cost control and efficiency improvements to enhance profitability in the upcoming quarters[24].

Financial Performance - The company's operating revenue for 2019 was CNY 3,699,941,990.20, representing a 15.02% increase compared to CNY 3,216,898,722.53 in 2018[11]. - The net profit attributable to shareholders for 2019 was CNY 1,283,449,049.98, an increase of 12.63% from CNY 1,139,512,936.78 in the previous year[11]. - The net profit after deducting non-recurring gains and losses was CNY 1,146,854,058.97, up 14.47% from CNY 1,001,922,313.02 in 2018[11]. - The net cash flow from operating activities was CNY 1,362,760,281.36, reflecting a 5.42% increase from CNY 1,292,636,143.37 in 2018[11]. - The total assets at the end of 2019 were CNY 7,583,197,994.71, a 16.79% increase from CNY 6,493,052,924.97 at the end of 2018[11]. - The net assets attributable to shareholders at the end of 2019 were CNY 6,543,127,592.63, an increase of 18.38% from CNY 5,527,197,894.65 in 2018[11]. - The basic earnings per share for 2019 were CNY 0.9148, up 12.00% from CNY 0.8168 in 2018[11]. - The diluted earnings per share for 2019 were also CNY 0.9148, reflecting the same growth of 12.00% compared to the previous year[11]. - The weighted average return on equity for 2019 was 19.89%, a decrease of 2.47% from 22.36% in 2018[11]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 4 per 10 shares, with a capital reserve conversion of 3 shares for every 10 shares held[2]. - A cash dividend of CNY 4 per 10 shares (totaling CNY 561,343,608.00) is proposed for distribution to shareholders, with no stock dividends planned[67]. - The cash dividend represents 43.74% of the net profit attributable to ordinary shareholders for 2019, which was CNY 1,283,449,049.98[66]. - The remaining undistributed profit after the dividend distribution will be carried forward to the next fiscal year, amounting to CNY 1,076,131,280.73[68]. - The company has maintained its cash dividend policy without any adjustments during the reporting period, ensuring compliance with its articles of association[63]. Research and Development - The company is actively engaged in the research and development of innovative drugs and biosimilars, with several clinical trial approvals already obtained[17]. - The company has obtained clinical trial approval for 7 monoclonal antibody products, with several currently in Phase III clinical trials[20]. - The company aims to enhance the production and sales of the quadrivalent influenza virus split vaccine, which has passed GMP certification[20]. - The company is focusing on optimizing the product structure of blood products and increasing the production of urgently needed products[19]. - The company is committed to developing innovative drugs and biosimilars to create new profit growth points[20]. - The company has established a comprehensive research and development platform for blood products, vaccines, and gene-engineered products, enhancing its innovation capabilities[24]. Market Position and Strategy - The blood products market is expected to grow due to increased healthcare awareness and aging population, with the company positioned to benefit from this trend[21]. - The company is actively seeking strategic partnerships and merger opportunities to enhance its core competitiveness[19]. - The company’s vaccine products are recognized for their strong preventive effects and high safety, addressing the significant vaccine demand in China[21]. - The company is the largest producer of influenza vaccines in China, with a market share ranking first domestically[24]. - The company has a comprehensive product structure with a high plasma utilization rate, maintaining a leading market share in several blood product categories[21]. Financial Management - The company has restricted assets totaling CNY 464,372,840.52, including structured deposits of CNY 455,000,000.00 and performance guarantees of CNY 766,218.07[46]. - The company has no significant equity or non-equity investments during the reporting period[47]. - The company’s financial liabilities remain at CNY 0.00, indicating no debt obligations[45]. - The company has not utilized any raised funds during the reporting period[49]. - The company has not disposed of any significant assets or equity during the reporting period[50]. Employee Management - The total number of employees in the company is 2,417, with 1,279 in production, 215 in sales, 681 in technical roles, 38 in finance, and 204 in administration[129]. - The company emphasizes employee training across various fields, including microbiology, safety, and professional knowledge, to enhance overall employee capabilities[131]. - The company has established a comprehensive compensation management system that adjusts salaries based on operational performance and regional living costs[130]. - The company has not engaged in labor outsourcing, maintaining a fully employed workforce[132]. Governance and Compliance - The company adheres to strict governance practices, complying with relevant laws and regulations to ensure operational integrity[133]. - The company has implemented various internal management systems, including investor relations and information disclosure management, to enhance transparency[134]. - The independent directors have fully reviewed the profit distribution plan and provided their consent, ensuring proper governance[63]. - The company has not faced any major litigation or arbitration matters during the reporting period[81]. - The company has not received any administrative regulatory measures from supervisory authorities during the reporting period[134]. Future Outlook - The company plans to expand its market presence and invest in new product development to drive future growth[164]. - The company aims to improve the comprehensive utilization rate of plasma through process optimization, new product development, and technological upgrades[56]. - The company is exploring potential mergers and acquisitions to strengthen its market position[192].

Financial Performance - Net profit attributable to shareholders rose by 48.96% to CNY 456,837,952.74 for the reporting period[8] - Operating revenue for the period reached CNY 1,235,831,935.34, reflecting a growth of 48.05% year-on-year[8] - Basic earnings per share were CNY 0.3256, a decrease of 1.24% compared to the same period last year[8] - The weighted average return on equity was 7.27%, an increase of 1.48% year-on-year[8] - Net profit for the quarter was ¥517,758,151.21, representing a 64.1% increase from ¥315,880,691.96 in the previous year[36] - The total comprehensive income for the third quarter was ¥517,758,151.21, compared to ¥315,880,691.96 in the previous year, indicating a significant increase[39] - The total comprehensive income attributable to the parent company was ¥456,837,952.74, compared to ¥306,682,234.67 in the previous year, showing a substantial increase[39] Assets and Liabilities - Total assets increased by 10.80% to CNY 7,194,582,532.49 compared to the end of the previous year[8] - The total assets amounted to approximately 7.19 billion yuan as of September 30, 2019, compared to approximately 6.49 billion yuan at the end of 2018[28] - The total liabilities amounted to approximately 674.29 million yuan, a decrease from approximately 720.47 million yuan in the previous year[28] - The total liabilities decreased to ¥141,613,878.66 from ¥205,876,756.99, a reduction of 31.2%[32] - The total equity increased to ¥3,933,848,230.45 from ¥3,789,510,537.48, showing a growth of 3.8%[33] Cash Flow - The net cash flow from operating activities decreased by 34.44% to CNY 221,924,800.25[8] - Cash flow from operating activities for the period was CNY 761,877,506.73, an increase of 5.8% compared to CNY 720,188,318.18 in the previous year[51] - Cash inflow from investment activities totaled CNY 3,730,281,303.10, down from CNY 3,989,697,083.89 in the previous period[55] - The ending balance of cash and cash equivalents decreased by 57.64% compared to the beginning of the period, primarily due to the company's investment of idle funds in financial products to improve capital efficiency[16] - Cash and cash equivalents at the end of the period were CNY 24,801,202.03, compared to CNY 15,017,373.85 at the end of the previous period, reflecting an increase of 65.1%[55] Expenses - The net cash flow from operating activities was CNY 274,897,026.12, down 52.3% from CNY 576,870,212.95 in the previous period[53] - Research and development expenses increased by 31.01% compared to the same period last year, reflecting higher R&D investments[16] - Sales expenses increased by 30.72% compared to the same period last year, mainly due to higher promotional consulting fees and salaries[16] - The company reported a significant increase in research and development expenses, which reached ¥36,877,457.16, compared to ¥28,659,689.65 in the previous year, reflecting a growth of 28.7%[35] - The income tax expenses increased by 36.22% compared to the same period last year, driven by increased operating profits leading to higher tax provisions[16] Shareholder Information - The total number of shareholders at the end of the reporting period was 46,869[12] - The top shareholder, An Kang, holds 17.86% of the shares, amounting to 250,525,693 shares[12] - The company did not engage in any repurchase transactions during the reporting period[13] Investment Activities - Investment income increased by 52.20% compared to the same period last year, mainly due to higher returns from financial investments[16] - The company reported investment income of ¥49,554,185.49, which is an increase from ¥22,482,569.98 in the previous year[39] Other Information - The company did not undergo an audit for the third quarter report[56] - The company’s chairman is An Kang, who provided insights during the earnings call[57]